A February 2026 paper published in the medical journal Pain Reports describes how a Canadian clinic specializing in pain management has validated a new pain measurement tool. The tool, named the Integral of Pain Relief (IPR), measures the changes in how a patient experiences pain over discrete time periods. It uses a simple mathematical formula to determine whether a patient is still feeling a benefit from the treatment days, weeks or months later. Led by Dr. Igor Wilderman, the authors say the IPR will allow clinicians and researchers to properly compare the effectiveness and duration of pain relief treatment options.
The Pain Problem
Because pain is so subjective, it is difficult to assess quantitatively. Despite this, patient-reported outcomes remain the most reliable tools to gauge whether the pain treatment is working. Commonly used pain measurement scales, like the Numeric Rating Scale (NRS) or the Patient’s Global Impression of Change (PGIC), do not account for an important dimension of pain relief – the duration . The IPR was developed to evaluate the percentage and duration of pain relief.
What’s more, doctors currently measure pain treatment outcomes with self-reported information from daily diaries and phone calls at specific fixed time points. Not only is this work intensive for the clinical staff and more prone to errors, inaccuracies, and incomplete data, but this method misses critical data on the duration of successful pain relief. The researchers designed the IPR to provide temporal information and reduce the monitoring burden on both patients and physicians.
Integral of Pain Relief Methodolgy
The IPR focuses on the participant’s perception of change over time. They are asked to estimate the percentage of pain relief (PPR) and days of relief since treatment initiation or from the previous time point on record. A clinician will then calculate the IPR according to the following formula:
IPR = (PPR x days of pain relief)/100
The formula adds up all the little changes that the patient reports from week to week to get a final number that represents the overall reduction in pain. Thus, the IPR provides a quantitative measure of change that can be used for statistical calculations, in contrast to more qualitative indicators like the PGIC.
Validating the Scale
To validate the IPR, the team compared its results to those obtained with other commonly used scales: the NRS, the PGIC, and the Western Ontario and McMaster University’s osteoarthritis index (WOMAC). The goal was to determine whether the IPR results reasonably correlated with the existing standard pain measurement scales.
The study was conducted at the Wilderman Medical Clinic (Thornhill, ON, Canada) on patients diagnosed with knee osteoarthritis who would be receiving corticosteroid injections as treatment. Baseline knee pain was assessed by the NRS and WOMAC followed by the inclusion of IPR and PGIC at weeks 2, 4, 6, 8, and 12 after the injection.
Did It Work?
The results, based on the 66 people included in the final analysis, showed that all measures were strongly correlated and that the IPR could properly recognize people responding well to their pain treatment. Not only that, but the IPR was also able to pinpoint a statistically significant sex difference, identifying more effective and prolonged pain relief in women compared to men.
The study confirms the validity and accuracy of the IPR as a new measure of long-term pain relief in patients with chronic pain, one that accounts for the strength and duration of effective pain control. The practical use case would be to allow for long-term comparisons of chronic pain treatments in a way that reduces the monitoring burden on patients and physicians. The IPR also lends itself to practitioners to make inferences on treatment efficacy from a single number, the data for which can be taken at any follow-up.
Next Steps?
Due to the relatively small number of final participants included in the analysis (N=66), more work should be done to assess how best this tool can be utilized clinically and statistically. This validation study was only done on a particular group of patients with chronic pain, those with knee osteoarthritis, but should be extrapolated to other chronic pain conditions for a more comprehensive understanding of the IPR.
In conclusion, the IPR has been validated as a measure of the efficacy and duration of pain relief offered, in this case, by steroid injections. Moreover, as a quantitative standard, its information can be used for in-depth statistical analysis, unlike the PGIC parameter. Adding the IPR as another tool in the toolkit to the traditional pain scales used in various diseases may be helpful in comparing the overall efficacy of different treatments for chronic pain.
Wilderman I, Zingerman O, Sarzetto F, Tsirulnikov M, Nezon E. Validation of the integral of pain relief as a measure of chronic pain treatment efficacy. PAIN Reports. 2026;11(1):e1373. doi:10.1097/PR9.0000000000001373